BAO PHARMA-B (02659) schedules 26 Mar 2026 board meeting to approve FY2025 annual results

Bulletin Express

03/16

Shanghai Bao Pharmaceuticals Co., Ltd. (BAO PHARMA-B, stock code: 02659) has announced that its board of directors will convene on 26 March 2026 in Shanghai. The primary agenda is to review and approve the consolidated financial results for the year ended 31 December 2025 and to authorize their publication.

The current board comprises 12 directors: • Executive Directors: Dr. Liu Yanjun (Chairman), Ms. Wang Zheng, Mr. Tan Jingwei, and Ms. Li Cui • Non-executive Directors: Ms. Lin Chia-ling, Mr. Diao Juanhuan, and Mr. Li Chen • Independent Non-executive Directors: Mr. Cai Zhongxi, Dr. Zeng Fanyi, Dr. Ju Dianwen, and Mr. Zhang Senquan

The company did not provide preliminary financial figures in this announcement; detailed performance metrics will be disclosed following the board’s approval of the FY2025 results later this month.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1113827952"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113827952\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113827952?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113827952","market":"hk","top_or_hot":-1,"title":"BAO PHARMA-B (02659) schedules 26 Mar 2026 board meeting to approve FY2025 annual results","media":"Bulletin Express","content":"<p>Shanghai Bao Pharmaceuticals Co., Ltd. (BAO PHARMA-B, stock code: 02659) has announced that its board of directors will convene on 26 March 2026 in Shanghai. The primary agenda is to review and approve the consolidated financial results for the year ended 31 December 2025 and to authorize their publication.</p>\n<p>The current board comprises 12 directors:\n• Executive Directors: Dr. Liu Yanjun (Chairman), Ms. Wang Zheng, Mr. Tan Jingwei, and Ms. Li Cui  \n• Non-executive Directors: Ms. Lin Chia-ling, Mr. Diao Juanhuan, and Mr. Li Chen  \n• Independent Non-executive Directors: Mr. Cai Zhongxi, Dr. Zeng Fanyi, Dr. Ju Dianwen, and Mr. Zhang Senquan</p>\n<p>The company did not provide preliminary financial figures in this announcement; detailed performance metrics will be disclosed following the board’s approval of the FY2025 results later this month.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAO PHARMA-B (02659) schedules 26 Mar 2026 board meeting to approve FY2025 annual results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAO PHARMA-B (02659) schedules 26 Mar 2026 board meeting to approve FY2025 annual results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-16 16:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shanghai Bao Pharmaceuticals Co., Ltd. (BAO PHARMA-B, stock code: 02659) has announced that its board of directors will convene on 26 March 2026 in Shanghai. The primary agenda is to review and approve the consolidated financial results for the year ended 31 December 2025 and to authorize their publication.</p>\n<p>The current board comprises 12 directors:\n• Executive Directors: Dr. Liu Yanjun (Chairman), Ms. Wang Zheng, Mr. Tan Jingwei, and Ms. Li Cui  \n• Non-executive Directors: Ms. Lin Chia-ling, Mr. Diao Juanhuan, and Mr. Li Chen  \n• Independent Non-executive Directors: Mr. Cai Zhongxi, Dr. Zeng Fanyi, Dr. Ju Dianwen, and Mr. Zhang Senquan</p>\n<p>The company did not provide preliminary financial figures in this announcement; detailed performance metrics will be disclosed following the board’s approval of the FY2025 results later this month.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"寶濟藥業-B","start_time":0,"source_url":"","article_id":"1113827952","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113827952","pubTimestamp":1773650538,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (BAO PHARMA-B, stock code: 02659) has announced that its board of directors will convene on 26 March 2026 in Shanghai. The primary agenda is to review and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"宝药业-B(02659)定于2026年3月26日召开董事会批准2025财年全年业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"Shanghai Bao Pharmaceuticals Co., Ltd. (BAO PHARMA-B, stock code: 02659) has announced that its board of directors will convene on 26 March 2026 in Shanghai. The primary agenda is to review and approve the consolidated financial results for the year ended 31 December 2025 and to authorize their publication.\nThe current board comprises 12 directors:\n• Executive Directors: Dr. Liu Yanjun (Chairman), Ms. Wang Zheng, Mr. Tan Jingwei, and Ms. Li Cui  \n• Non-executive Directors: Ms. Lin Chia-ling, Mr. Diao Juanhuan, and Mr. Li Chen  \n• Independent Non-executive Directors: Mr. Cai Zhongxi, Dr. Zeng Fanyi, Dr. Ju Dianwen, and Mr. Zhang Senquan\nThe company did not provide preliminary financial figures in this announcement; detailed performance metrics will be disclosed following the board’s approval of the FY2025 results later this month.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}